Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.

Cancer science - 1 Apr 2020

Lin Po-Han, Chen Ming, Tsai Li-Wei, Lo Chiao, Yen Tzu-Chun, Huang Thomas Yoyan, Chen Chih-Kai, Fan Sheng-Chih, Kuo Sung-Hsin, Huang Chiun-Sheng

Abstract excerpt

BRCAness is considered a predictive biomarker to platinum and poly(ADP-ribose) polymerase (PARP) inhibitors. However, recent trials showed that its predictive value was limited in triple-negative breast cancer (TNBC) treated with platinum. Moreover, tumors with mutations of DNA damage response (DDR) genes, such as homologous recombination (HR) genes, could be sensitive to platinum and PARP inhibitors. Thus, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Damage

Share to Homologous Recombination

Share to Platinum

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Triple Negative Breast Neoplasms

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 31958182
DOI: 10.1111/cas.14313
PMCID: PMC7156820

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.PMID 31958182Read ↗

Next-Generation Sequencing and Triple-Negative Breast Cancer: Insights and Applications.Semantic proximity Read ↗

BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.Semantic proximity Read ↗

Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancerSemantic proximity Read ↗

TP53-specific mutations serve as a potential biomarker for homologous recombination deficiency in breast cancer: a clinical next-generation sequencing studySemantic proximity Read ↗

Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancerSemantic proximity Read ↗

Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 TrialSemantic proximity Read ↗

Somatic mutations in four novel genes contribute to homologous recombination deficiency in breast cancer: a real-world clinical tumor sequencing study.Semantic proximity Read ↗

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.Semantic proximity Read ↗

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.Semantic proximity Read ↗

A novel targeted NGS panel identifies numerous homologous recombination deficiency (HRD)-associated gene mutations in addition to known BRCA mutations.Semantic proximity Read ↗

Effects of germline and somatic events in candidate BRCAness genes on breast-tumor signaturesSemantic proximity Read ↗

[Application value of DNA damage repair variants in adjuvant therapy of triple negative breast cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.